Trial Profile
Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites in Healthy Elderly Subjects Compared With Those in Healthy Young Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Bial
- 18 Apr 2017 Status changed from discontinued to completed.
- 30 Jun 2014 New trial record